---
schema_version: "secwatch.filing_event.v1"
accession: "0001641489-25-000051"
form_type: "8-K"
ticker: "VTVT"
cik: "0001641489"
company_name: "vTv Therapeutics Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:36:52.773629+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# vTv Therapeutics Q2 net loss $6.0M; Phase 3 T1D trial randomized

## Summary
- Net loss attributable to vTv shareholders of $6.0M ($0.92/share) vs $5.2M ($0.81/share) in Q2 2024.
- Cash and cash equivalents $25.9M at June 30, 2025, down from $36.7M at December 31, 2024.
- First patient randomized in Phase 3 CATT1 trial of cadisegliatin for type 1 diabetes; topline data expected H2 2026.
- Appointed Michael Tung, MD, MBA as CFO in May 2025.
- USPTO allowed patent claims for crystalline salt form of cadisegliatin with term through 2041.

## SEC filing metadata
- accession: 0001641489-25-000051
- form_type: 8-K
- ticker: VTVT
- cik: 0001641489
- company_name: vTv Therapeutics Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641489/000164148925000051/0001641489-25-000051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641489/000164148925000051/vtvt-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641489-25-000051
- JSON: https://secwatch.observer/filing/0001641489-25-000051.json
- Plain text: https://secwatch.observer/filing/0001641489-25-000051.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.